Terms: = Breast cancer AND PTK6, BRK, 5753, ENSG00000101213, Q13882, FLJ42088
115 results:
1. MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative breast cancer Metastases.
Ito K; Harada I; Martinez C; Sato K; Lee E; Port E; Byerly JH; Nayak A; Tripathi E; Zhu J; Irie HY
Cancer Res Commun; 2024 Mar; 4(3):946-957. PubMed ID: 38457262
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic impact of ptk6 expression in triple negative breast cancer.
Chen Y; Qu W; Tu J; Yang L; Gui X
BMC Womens Health; 2023 Nov; 23(1):575. PubMed ID: 37932734
[TBL] [Abstract] [Full Text] [Related]
3. Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer.
Dai LJ; Ma D; Xu YZ; Li M; Li YW; Xiao Y; Jin X; Wu SY; Zhao YX; Wang H; Yang WT; Jiang YZ; Shao ZM
Nat Commun; 2023 Aug; 14(1):5112. PubMed ID: 37607916
[TBL] [Abstract] [Full Text] [Related]
4. brk/ptk6 and Involucrin Expression May Predict breast cancer Cell Responses to Vitamin D3.
Box C; Pennington C; Hare S; Porter S; Edwards D; Eccles S; Crompton M; Harvey A
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445934
[TBL] [Abstract] [Full Text] [Related]
5. brk confers tamoxifen-resistance in breast cancer via regulation of tyrosine phosphorylation of CDK1.
Mandapati A; Ning Z; Baharani A; Lukong KE
Cell Signal; 2023 Aug; 108():110723. PubMed ID: 37216999
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive Analysis Reveals ptk6 as a Prognostic Biomarker Involved in the Immunosuppressive Microenvironment in breast cancer.
Wang L; Luo S; Wang Z; Huang Y; Luo Y; Xie X
J Immunol Res; 2022; 2022():5160705. PubMed ID: 36405012
[TBL] [Abstract] [Full Text] [Related]
7. breast Tumour Kinase (brk/ptk6) Contributes to breast Tumour Xenograft Growth and Modulates Chemotherapeutic Responses In Vitro.
Burmi RS; Box GM; Wazir U; Hussain HA; Davies JA; Court WJ; Eccles SA; Jiang WG; Mokbel K; Harvey AJ
Genes (Basel); 2022 Feb; 13(3):. PubMed ID: 35327957
[TBL] [Abstract] [Full Text] [Related]
8. A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis.
Brufsky A; Kim SB; Zvirbule Ž; Eniu A; Mebis J; Sohn JH; Wongchenko M; Chohan S; Amin R; Yan Y; McNally V; Miles D; Loi S
Ann Oncol; 2021 May; 32(5):652-660. PubMed ID: 33539944
[TBL] [Abstract] [Full Text] [Related]
9. Putting the brk on breast cancer: From molecular target to therapeutics.
Ang HL; Yuan Y; Lai X; Tan TZ; Wang L; Huang BB; Pandey V; Huang RY; Lobie PE; Goh BC; Sethi G; Yap CT; Chan CW; Lee SC; Kumar AP
Theranostics; 2021; 11(3):1115-1128. PubMed ID: 33391524
[TBL] [Abstract] [Full Text] [Related]
10. breast Tumor Kinase (brk/ptk6) Mediates Advanced cancer Phenotypes via SH2-Domain Dependent Activation of RhoA and Aryl Hydrocarbon Receptor (AhR) Signaling.
Dwyer AR; Kerkvliet CP; Krutilina RI; Playa HC; Parke DN; Thomas WA; Smeester BA; Moriarity BS; Seagroves TN; Lange CA
Mol Cancer Res; 2021 Feb; 19(2):329-345. PubMed ID: 33172975
[TBL] [Abstract] [Full Text] [Related]
11. Targeting protein tyrosine kinase 6 in cancer.
Gilic MB; Tyner AL
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188432. PubMed ID: 32956764
[TBL] [Abstract] [Full Text] [Related]
12. Strategic Developments & Future Perspective on Gene Therapy for breast cancer: Role of mTOR and brk/ ptk6 as Molecular Targets.
Sahu R; Pattanayak SP
Curr Gene Ther; 2020; 20(4):237-258. PubMed ID: 32807051
[TBL] [Abstract] [Full Text] [Related]
13. Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets.
Paul MR; Pan TC; Pant DK; Shih NN; Chen Y; Harvey KL; Solomon A; Lieberman D; Morrissette JJ; Soucier-Ernst D; Goodman NG; Stavropoulos SW; Maxwell KN; Clark C; Belka GK; Feldman M; DeMichele A; Chodosh LA
J Clin Invest; 2020 Aug; 130(8):4252-4265. PubMed ID: 32657779
[TBL] [Abstract] [Full Text] [Related]
14. brk phosphorylates SMAD4 for proteasomal degradation and inhibits tumor suppressor FRK to control SNAIL, SLUG, and metastatic potential.
Miah S; Banks CAS; Ogunbolude Y; Bagu ET; Berg JM; Saraf A; Tettey TT; Hattem G; Dayebgadoh G; Kempf CG; Sardiu M; Napper S; Florens L; Lukong KE; Washburn MP
Sci Adv; 2019 Oct; 5(10):eaaw3113. PubMed ID: 31681835
[TBL] [Abstract] [Full Text] [Related]
15. Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells.
Miah S; Bagu E; Goel R; Ogunbolude Y; Dai C; Ward A; Vizeacoumar FS; Davies G; Vizeacoumar FJ; Anderson D; Lukong KE
BMC Cancer; 2019 Jan; 19(1):78. PubMed ID: 30651078
[TBL] [Abstract] [Full Text] [Related]
16. Taxol Induces brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.
Regan Anderson TM; Ma S; Perez Kerkvliet C; Peng Y; Helle TM; Krutilina RI; Raj GV; Cidlowski JA; Ostrander JH; Schwertfeger KL; Seagroves TN; Lange CA
Mol Cancer Res; 2018 Nov; 16(11):1761-1772. PubMed ID: 29991529
[TBL] [Abstract] [Full Text] [Related]
17. 13
Souid S; Elsayed HE; Ebrahim HY; Mohyeldin MM; Siddique AB; Karoui H; El Sayed KA; Essafi-Benkhadir K
Mol Carcinog; 2018 Nov; 57(11):1507-1524. PubMed ID: 29978911
[TBL] [Abstract] [Full Text] [Related]
18. Small molecule inhibitors reveal ptk6 kinase is not an oncogenic driver in breast cancers.
Qiu L; Levine K; Gajiwala KS; Cronin CN; Nagata A; Johnson E; Kraus M; Tatlock J; Kania R; Foley T; Sun S
PLoS One; 2018; 13(6):e0198374. PubMed ID: 29879184
[TBL] [Abstract] [Full Text] [Related]
19. Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in breast cancer Cells.
Patel P; Tsiperson V; Gottesman SRS; Somma J; Blain SW
Mol Cancer Res; 2018 Mar; 16(3):361-377. PubMed ID: 29330290
[TBL] [Abstract] [Full Text] [Related]
20. Descriptive characteristics of prostate cancer in patients with a history of primary male breast cancer - a SEER analysis.
Abhyankar N; Hoskins KF; Abern MR; Calip GS
BMC Cancer; 2017 Sep; 17(1):659. PubMed ID: 28946846
[TBL] [Abstract] [Full Text] [Related]
[Next]
